Prostate cancer prognostic compositions and kits
First Claim
1. A method for characterizing prostate cancer in a biological sample of a subject comprising:
- a) synthesizing PCA3 cDNA from a prostate cancer specific PCA3 mRNA from the biological sample;
b) measuring the amount of the synthesized PCA3 cDNA;
c) measuring an amount of PSA in the biological sample; and
d) determining a ratio value of the amount of the synthesized PCA3 cDNA over the amount of PSA.
2 Assignments
0 Petitions
Accused Products
Abstract
Described herein are method, compositions and kits for prognosis of prostate cancer. The methods include determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The method for prognosing prostate cancer in a sample of a patient includes assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.
73 Citations
20 Claims
-
1. A method for characterizing prostate cancer in a biological sample of a subject comprising:
-
a) synthesizing PCA3 cDNA from a prostate cancer specific PCA3 mRNA from the biological sample; b) measuring the amount of the synthesized PCA3 cDNA; c) measuring an amount of PSA in the biological sample; and d) determining a ratio value of the amount of the synthesized PCA3 cDNA over the amount of PSA. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
-
14. A method for characterizing prostate cancer in a biological sample comprising:
-
a) contacting a biological sample with one or more first oligonucleotides that hybridize to a prostate cancer specific PCA3 mRNA or a complement thereof; b) contacting the biological sample with one or more second oligonucleotides that hybridize to a PSA mRNA or a complement thereof; c) determining the amount of PCA3 mRNA and the amount of PSA mRNA present in the biological sample; d) determining a ratio value of the amount of PCA3 mRNA over the amount of PSA mRNA, wherein the one or more first oligonucleotides comprise at least one of an artificially labeled oligonucleotide or a promoter-primer. - View Dependent Claims (15, 16, 17, 18, 19, 20)
-
Specification